Newsfeeds - Spark Newswire

4 minute read

Israeli Ministry Of Health Clears Way For Human Trials Of Allocetra

December 1, 3:02 PM

The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ:ENLV) proprietary immunotherapy drug-candidate AllocetraTM. AllocetraTM is a cell therapy that uses healthy

BMY

1 minute read

News

Enlivex Therapeutics Granted U.S. Patent #11512289: Combination immune therapy and cytokine control therapy for cancer treatment

By Charles Gross

November 29, 6:37 AM

https://www.scribd.com/document/611028809/ENLV-Patent

ENLV

1 minute read

Enlivex Receives Israeli Ministry Of Health Approval For The Initiation Of A Phase I/II Trial Evaluating Allocetra Alone And In Combination With A PD1 Checkpoint Inhibitor In Patients With Advanced Solid Tumors

By Benzinga Newsdesk

August 17, 8:10 AM

Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined with PD1

ENLV

3 minute read

Sheba Medical Center and Enlivex Announce Dosing Of The First Patient In Phase I/II Trial Evaluating Allocetra Combined With Chemotherapy In Patients With Peritoneal Metastases Arising From Solid Cancers

By Bill Haddad

July 6, 8:37 AM

First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic effects in solid tumor models Sheba Medical Center was

ENLV

1 minute read

Legal
News

Enlivex Announces Issuance Of Two U.S. Patents Covering Methods Of Treating Sepsis With Allocetra

By Benzinga Newsdesk

May 5, 8:38 AM

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the ", Company", )))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each

ENLV

1 minute read

HC Wainwright & Co. Maintains Buy on Enlivex Therapeutics, Lowers Price Target to $15

By Benzinga Newsdesk

May 2, 6:15 AM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and lowers the price target from $33 to $15.

ENLV

1 minute read

News

Enlivex Therapeutics Granted U.S. Patent #11,304,976 ‘Combination immune therapy and cytokine control therapy for cancer treatment’

By Charles Gross

April 19, 7:26 AM

View Patent here

ENLV

1 minute read

Legal
News

Enlivex Therapeutics Reports Issuance Of Israeli Patent Covering Allocetra Derived From Pooled Donor Cells

By Benzinga Newsdesk

March 8, 9:04 AM

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the &ldquo, Company&rdquo, )), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of Israeli Patent Number 255119 entitled,

ENLV

6 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

February 3, 11:49 AM

On Thursday, 105 stocks hit new 52-week lows.

ALPN

2 minute read

News

Enlivex Therapeutics Reports Spanish Regulator Granted Co. Authorization To Expand Sepsis Phase 2 Trial Into Spain

By Benzinga Newsdesk

November 4, 8:18 AM

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the &ldquo, Company&rdquo, )), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has

ENLV